Published in Nat Struct Biol on May 01, 2003
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci U S A (2008) 4.80
Plasmodium falciparum isolates in India exhibit a progressive increase in mutations associated with sulfadoxine-pyrimethamine resistance. Antimicrob Agents Chemother (2004) 2.04
Drug-resistant malaria - an insight. FEBS J (2007) 1.54
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. Nat Chem Biol (2009) 1.52
Artemisinins: their growing importance in medicine. Trends Pharmacol Sci (2008) 1.43
Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance. Trends Mol Med (2006) 1.42
Linkage group selection: rapid gene discovery in malaria parasites. Genome Res (2005) 1.33
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. J Med Chem (2011) 1.28
Compensatory mutations restore fitness during the evolution of dihydrofolate reductase. Mol Biol Evol (2010) 1.27
Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase. J Med Chem (2008) 1.26
Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci U S A (2012) 1.26
Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc Natl Acad Sci U S A (2005) 1.22
Exploring the folate pathway in Plasmodium falciparum. Acta Trop (2005) 1.20
Quadruple mutations in dihydrofolate reductase of Plasmodium falciparum isolates from Car Nicobar Island, India. Antimicrob Agents Chemother (2006) 1.15
Targeting purine and pyrimidine metabolism in human apicomplexan parasites. Curr Drug Targets (2007) 1.14
Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis (2008) 1.10
Selective peptide inhibitors of bifunctional thymidylate synthase-dihydrofolate reductase from Toxoplasma gondii provide insights into domain-domain communication and allosteric regulation. Protein Sci (2013) 1.10
Two crystal structures of dihydrofolate reductase-thymidylate synthase from Cryptosporidium hominis reveal protein-ligand interactions including a structural basis for observed antifolate resistance. Acta Crystallogr Sect F Struct Biol Cryst Commun (2005) 1.08
In pursuit of virtual lead optimization: the role of the receptor structure and ensembles in accurate docking. Proteins (2008) 1.01
Pyrimethamine-resistant dihydrofolate reductase enzymes of Plasmodium falciparum are not enzymatically compromised in vitro. Mol Biochem Parasitol (2007) 1.01
In pursuit of virtual lead optimization: pruning ensembles of receptor structures for increased efficiency and accuracy during docking. Proteins (2009) 0.98
First three-dimensional structure of Toxoplasma gondii thymidylate synthase-dihydrofolate reductase: insights for catalysis, interdomain interactions, and substrate channeling. Biochemistry (2013) 0.95
Antifolate agents: a patent review (2006 - 2010). Expert Opin Ther Pat (2011) 0.95
Purine and pyrimidine pathways as targets in Plasmodium falciparum. Curr Top Med Chem (2011) 0.93
Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania. Malar J (2006) 0.93
Crystal structure of arginase from Plasmodium falciparum and implications for L-arginine depletion in malarial infection . Biochemistry (2010) 0.92
Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo. Antimicrob Agents Chemother (2005) 0.92
Probing the role of parasite-specific, distant structural regions on communication and catalysis in the bifunctional thymidylate synthase-dihydrofolate reductase from Plasmodium falciparum. Biochemistry (2008) 0.92
Discovery: an interactive resource for the rational selection and comparison of putative drug target proteins in malaria. Malar J (2009) 0.89
Parasite-specific inserts in the bifunctional S-adenosylmethionine decarboxylase/ornithine decarboxylase of Plasmodium falciparum modulate catalytic activities and domain interactions. Biochem J (2004) 0.88
Exploiting structural analysis, in silico screening, and serendipity to identify novel inhibitors of drug-resistant falciparum malaria. ACS Chem Biol (2009) 0.86
Accessible mutational trajectories for the evolution of pyrimethamine resistance in the malaria parasite Plasmodium vivax. J Mol Evol (2013) 0.86
Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination. Antimicrob Agents Chemother (2007) 0.86
Evolutionary patterning: a novel approach to the identification of potential drug target sites in Plasmodium falciparum. PLoS One (2008) 0.85
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate. Antimicrob Agents Chemother (2010) 0.85
Evaluation of the activities of pyrimethamine analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate reductase-thymidylate synthase using in vitro enzyme inhibition and bacterial complementation assays. Antimicrob Agents Chemother (2006) 0.85
X-ray structure of the ternary MTX.NADPH complex of the anthrax dihydrofolate reductase: a pharmacophore for dual-site inhibitor design. J Struct Biol (2009) 0.84
Prized malaria drug target nailed. Nat Struct Biol (2003) 0.84
Computer-aided molecular design of 1H-imidazole-2,4-diamine derivatives as potential inhibitors of Plasmodium falciparum DHFR enzyme. J Mol Model (2010) 0.84
Deletion mutagenesis of large areas in Plasmodium falciparum genes: a comparative study. Malar J (2007) 0.84
Electrostatic channeling in P. falciparum DHFR-TS: Brownian dynamics and Smoluchowski modeling. Biophys J (2014) 0.84
Towards genome-wide experimental genetics in the in vivo malaria model parasite Plasmodium berghei. Pathog Glob Health (2015) 0.83
Cloning and heterologous expression of Plasmodium ovale dihydrofolate reductase-thymidylate synthase gene. Parasitol Int (2012) 0.83
Transition-state inhibitors of purine salvage and other prospective enzyme targets in malaria. Future Med Chem (2013) 0.83
The molecular basis of folate salvage in Plasmodium falciparum: characterization of two folate transporters. J Biol Chem (2011) 0.81
Winning the arms race by improving drug discovery against mutating targets. ACS Chem Biol (2011) 0.81
Genotyping of Plasmodium falciparum pyrimethamine resistance by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry. Antimicrob Agents Chemother (2004) 0.81
Integration and mining of malaria molecular, functional and pharmacological data: how far are we from a chemogenomic knowledge space? Malar J (2006) 0.81
Combined spatial limitation around residues 16 and 108 of Plasmodium falciparum dihydrofolate reductase explains resistance to cycloguanil. Antimicrob Agents Chemother (2012) 0.81
Inhibitor-bound complexes of dihydrofolate reductase-thymidylate synthase from Babesia bovis. Acta Crystallogr Sect F Struct Biol Cryst Commun (2011) 0.81
Disruption of the crossover helix impairs dihydrofolate reductase activity in the bifunctional enzyme TS-DHFR from Cryptosporidium hominis. Biochem J (2009) 0.80
Modeling the inhibition of quadruple mutant Plasmodium falciparum dihydrofolate reductase by pyrimethamine derivatives. J Comput Aided Mol Des (2007) 0.80
Resistance of a rodent malaria parasite to a thymidylate synthase inhibitor induces an apoptotic parasite death and imposes a huge cost of fitness. PLoS One (2011) 0.80
Computational analysis of binding between malarial dihydrofolate reductases and anti-folates. Malar J (2010) 0.80
Biochemical and functional characterization of Plasmodium falciparum GTP cyclohydrolase I. Malar J (2014) 0.80
Transgenic Plasmodium parasites stably expressing Plasmodium vivax dihydrofolate reductase-thymidylate synthase as in vitro and in vivo models for antifolate screening. Malar J (2011) 0.79
WISDOM-II: screening against multiple targets implicated in malaria using computational grid infrastructures. Malar J (2009) 0.79
Interactions between cycloguanil derivatives and wild type and resistance-associated mutant Plasmodium falciparum dihydrofolate reductases. J Comput Aided Mol Des (2009) 0.79
Distribution of Plasmodium vivax pvdhfr and pvdhps alleles and their association with sulfadoxine-pyrimethamine treatment outcomes in Indonesia. Malar J (2015) 0.79
Trypanosoma brucei DHFR-TS Revisited: Characterisation of a Bifunctional and Highly Unstable Recombinant Dihydrofolate Reductase-Thymidylate Synthase. PLoS Negl Trop Dis (2016) 0.78
Modeling the evolution of drug resistance in malaria. J Comput Aided Mol Des (2012) 0.78
Genetic polymorphisms associated with sulphadoxine-pyrimethamine drug resistance among Plasmodium falciparum field isolates in malaria endemic areas of Assam. J Postgrad Med (2014) 0.78
Homology building as a means to define antigenic epitopes on dihydrofolate reductase (DHFR) from Plasmodium falciparum. Malar J (2004) 0.77
Selection of drug resistant mutants from random library of Plasmodium falciparum dihydrofolate reductase in Plasmodium berghei model. Malar J (2011) 0.76
Role of mutations in dihydrofolate reductase DfrA (Rv2763c) and thymidylate synthase ThyA (Rv2764c) in Mycobacterium tuberculosis drug resistance. Antimicrob Agents Chemother (2010) 0.76
Exploring novel strategies for AIDS protozoal pathogens: α-helix mimetics targeting a key allosteric protein-protein interaction in C. hominis TS-DHFR. Medchemcomm (2013) 0.75
Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future. Acta Crystallogr F Struct Biol Commun (2015) 0.75
Parametrization of halogen bonds in the CHARMM general force field: Improved treatment of ligand-protein interactions. Bioorg Med Chem (2016) 0.75
Crystal structure of 4,6-di-amino-2,2-dimethyl-3-[3-(2,4,5-tri-chloro-phen-oxy)prop-oxy]-2,3-di-hydro-1,3,5-triazin-1-ium chloride methanol monosolvate. Acta Crystallogr E Crystallogr Commun (2015) 0.75
Herbicidal properties of antimalarial drugs. Sci Rep (2017) 0.75
Binding modes of 2,4-diaminoquinazoline and 2,4-diaminopteridine analogs to P. falciparum dihydrofolate reductase enzyme: Molecular docking studies. Indian J Pharm Sci (2010) 0.75
Insights into the role of the junctional region of Plasmodium falciparum dihydrofolate reductase-thymidylate synthase. Malar J (2013) 0.75
Antifolate Agents Against Wild and Mutant Strains of Plasmodium falciparum. Indian J Pharm Sci (2014) 0.75
Structure-activity relationship and comparative docking studies for cycloguanil analogs as PfDHFR-TS inhibitors. J Chem Inf Model (2009) 0.75
Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature (2002) 37.66
Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol Syst Biol (2007) 8.16
Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol (2004) 3.45
Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci U S A (2009) 2.57
MeCP2 binding to DNA depends upon hydration at methyl-CpG. Mol Cell (2008) 2.48
Protein recognition of macrocycles: binding of anti-HIV metallocyclams to lysozyme. Proc Natl Acad Sci U S A (2005) 2.31
Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int (2005) 2.29
Predictive adaptive responses to maternal high-fat diet prevent endothelial dysfunction but not hypertension in adult rat offspring. Circulation (2004) 2.28
The pluripotency rheostat Nanog functions as a dimer. Biochem J (2008) 1.97
Molecular architecture of the Mos1 paired-end complex: the structural basis of DNA transposition in a eukaryote. Cell (2009) 1.88
Use of a computerized guideline for glucose regulation in the intensive care unit improved both guideline adherence and glucose regulation. J Am Med Inform Assoc (2004) 1.85
Clinical Practice Guidelines and Recommendations on Peritoneal Dialysis Adequacy 2011. Perit Dial Int (2011) 1.76
Computer-aided detection in the United Kingdom National Breast Screening Programme: prospective study. Radiology (2005) 1.63
Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. Mol Biochem Parasitol (2002) 1.62
Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. Proc Natl Acad Sci U S A (2005) 1.57
Mechanism of Mos1 transposition: insights from structural analysis. EMBO J (2006) 1.48
Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol (2006) 1.47
Extensive DNA mimicry by the ArdA anti-restriction protein and its role in the spread of antibiotic resistance. Nucleic Acids Res (2009) 1.38
A genetically hard-wired metabolic transcriptome in Plasmodium falciparum fails to mount protective responses to lethal antifolates. PLoS Pathog (2008) 1.37
Global proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome". Cell (2011) 1.34
Atomic structure of Mycobacterium tuberculosis CYP121 to 1.06 A reveals novel features of cytochrome P450. J Biol Chem (2002) 1.31
Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci U S A (2012) 1.26
Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc Natl Acad Sci U S A (2005) 1.22
Novel antifolate resistant mutations of Plasmodium falciparum dihydrofolate reductase selected in Escherichia coli. Mol Biochem Parasitol (2002) 1.18
Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol (2013) 1.17
S-nitrosylation of AtSABP3 antagonizes the expression of plant immunity. J Biol Chem (2008) 1.16
Dietary soy isoflavone induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo. FASEB J (2005) 1.14
A structure-based mutational analysis of cyclophilin 40 identifies key residues in the core tetratricopeptide repeat domain that mediate binding to Hsp90. J Biol Chem (2002) 1.13
Characterization, crystallization and preliminary X-ray analysis of bifunctional dihydrofolate reductase-thymidylate synthase from Plasmodium falciparum. Acta Crystallogr D Biol Crystallogr (2004) 1.13
Visuomotor priming by pictures of hand postures: perspective matters. Neuropsychologia (2003) 1.12
Octaheme tetrathionate reductase is a respiratory enzyme with novel heme ligation. Nat Struct Mol Biol (2004) 1.10
Evaluation of an ethnopharmacologically selected Bhutanese medicinal plants for their major classes of phytochemicals and biological activities. J Ethnopharmacol (2011) 1.10
M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation. Proc Natl Acad Sci U S A (2013) 1.10
Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med (2012) 1.09
Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure (2003) 1.09
A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J (2005) 1.08
Multi-intervention management of calciphylaxis: a report of 7 cases. Am J Kidney Dis (2011) 1.08
Epidermal growth factor receptor phosphorylation sites Ser991 and Tyr998 are implicated in the regulation of receptor endocytosis and phosphorylations at Ser1039 and Thr1041. Mol Cell Proteomics (2009) 1.07
Allosteric mechanism of pyruvate kinase from Leishmania mexicana uses a rock and lock model. J Biol Chem (2010) 1.06
Pyrimethamine analogs as strong inhibitors of double and quadruple mutants of dihydrofolate reductase in human malaria parasites. Org Biomol Chem (2003) 1.04
Homologues of human macrophage migration inhibitory factor from a parasitic nematode. Gene cloning, protein activity, and crystal structure. J Biol Chem (2002) 1.04
Expression, purification and preliminary crystallographic studies of a single-point mutant of Mos1 mariner transposase. Acta Crystallogr D Biol Crystallogr (2004) 1.03
Consensus docking: improving the reliability of docking in a virtual screening context. J Chem Inf Model (2013) 1.02
2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem (2004) 1.02
Configurations of nickel-cyclam antiviral complexes and protein recognition. Chemistry (2007) 1.02
A systematic review of computer-assisted diagnosis in diagnostic cancer imaging. Eur J Radiol (2011) 1.02
Structural and functional studies of the biotin protein ligase from Aquifex aeolicus reveal a critical role for a conserved residue in target specificity. J Mol Biol (2009) 1.01
Pyrimethamine-resistant dihydrofolate reductase enzymes of Plasmodium falciparum are not enzymatically compromised in vitro. Mol Biochem Parasitol (2007) 1.01
Inducible knockdown of Plasmodium gene expression using the glmS ribozyme. PLoS One (2013) 1.01
Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue. Clin Proteomics (2012) 1.01
Folate metabolism as a source of molecular targets for antimalarials. Future Microbiol (2006) 1.01
Crystallographic and mass spectrometric characterisation of eIF4E with N7-alkylated cap derivatives. J Mol Biol (2007) 1.01
The trypanocidal drug suramin and other trypan blue mimetics are inhibitors of pyruvate kinases and bind to the adenosine site. J Biol Chem (2011) 1.00
Analysis in Escherichia coli of Plasmodium falciparum dihydropteroate synthase (DHPS) alleles implicated in resistance to sulfadoxine. Int J Parasitol (2004) 0.99
Making decisions about mammography. BMJ (2005) 0.99
Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine-resistant Plasmodium falciparum. J Med Chem (2002) 0.99
Measurement of protein phosphorylation stoichiometry by selected reaction monitoring mass spectrometry. J Proteome Res (2010) 0.99
Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities. J Med Chem (2004) 0.98
Structures of immunophilins and their ligand complexes. Curr Top Med Chem (2003) 0.98
Comparative proteomic profiles and the potential markers between Burkholderia pseudomallei and Burkholderia thailandensis. Mol Cell Probes (2006) 0.98
Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum. J Med Chem (2004) 0.98
Crystal structure of a thermostable lipase from Bacillus stearothermophilus P1. J Mol Biol (2002) 0.98
Oxygen activation and electron transfer in flavocytochrome P450 BM3. J Am Chem Soc (2003) 0.97
System-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma. Clin Cancer Res (2010) 0.97
Intravenous ascorbic acid: protocol for its application and use. P R Health Sci J (2003) 0.96
EDULISS: a small-molecule database with data-mining and pharmacophore searching capabilities. Nucleic Acids Res (2010) 0.96
Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure (2003) 0.96
Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc Natl Acad Sci U S A (2009) 0.96
Stoichiometric selection of tight-binding inhibitors by wild-type and mutant forms of malarial (Plasmodium falciparum) dihydrofolate reductase. Anal Chem (2005) 0.95